Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

2008 Journal of Clinical Oncology 775 citations

Abstract

Purpose This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patients and Methods Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m 2 via 24-hour infusion, leucovorin 200 mg/m 2 , and oxaliplatin 85 mg/m 2 (FLO) every 2 weeks or fluorouracil 2,000 mg/m 2 via 24-hour infusion, leucovorin 200 mg/m 2 weekly, and cisplatin 50 mg/m 2 every 2 weeks (FLP). The primary end point was progression-free survival (PFS). Results Two hundred twenty patients (median age, 64 years; metastatic, 94%) were randomly assigned. FLO was associated with significantly less (any grade) anemia (54% v 72%), nausea (53% v 70%), vomiting (31% v 52%), alopecia (22% v 39%), fatigue (19% v 34%), renal toxicity (11% v 34%), thromboembolic events (0.9% v 7.8%), and serious adverse events related to the treatment (9% v 19%). FLP was associated with significantly less peripheral neuropathy (22% v 63%). There was a trend toward improved median PFS with FLO versus FLP (5.8 v 3.9 months, respectively; P = .077) and no significant difference in median overall survival (10.7 v 8.8 months, respectively). However, in patients older than 65 years (n = 94), treatment with FLO resulted in significantly superior response rates (41.3% v 16.7%; P = .012), time to treatment failure (5.4 v 2.3 months; P < .001), and PFS (6.0 v 3.1 month; P = .029) and an improved OS (13.9 v 7.2 months) as compared with FLP, respectively. Conclusion FLO reduced toxicity as compared with FLP. In older adult patients, FLO also seemed to be associated with improved efficacy.

Keywords

MedicineOxaliplatinFluorouracilGastroenterologyNauseaInternal medicineVomitingPhases of clinical researchChemotherapyAnemiaSurgeryCisplatinProgression-free survivalCancerColorectal cancer

Affiliated Institutions

Related Publications

Publication Info

Year
2008
Type
article
Volume
26
Issue
9
Pages
1435-1442
Citations
775
Access
Closed

External Links

Citation Metrics

775
OpenAlex

Cite This

Salah‐Eddin Al‐Batran, J. T. Hartmann, Stephan Probst et al. (2008). Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology , 26 (9) , 1435-1442. https://doi.org/10.1200/jco.2007.13.9378

Identifiers

DOI
10.1200/jco.2007.13.9378